Cancer Prevention starts Phase II of CPP-1x to prevent gastric cancer

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.) began a Phase II trial of CPP-1X to prevent gastric cancer in patients with precancerous gastric lesions. The double-blind, placebo-controlled trial will evaluate 500 mg daily oral CPP-1X for 18 months in about 300 patients.

The trial’s primary endpoint is cell DNA damage at 6 months. Secondary endpoints include cell DNA damage at 18 months, gastritis histopathology score and safety. NCI is funding the trial...